Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1113
Abstract: Tralokinumab is the first biologic therapy for moderate‐to‐severe atopic dermatitis (AD) that specifically neutralizes interleukin‐13 activity, a key driver of AD signs and symptoms. Tralokinumab is a human immunoglobulin G4 monoclonal antibody administered subcutaneously every… read more here.
Keywords: severe atopic; moderate severe; atopic dermatitis; exposure ... See more keywords
A set of clinical and laboratory markers differentiates hyper-IgE syndrome from severe atopic dermatitis.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical immunology"
DOI: 10.1016/j.clim.2020.108645
Abstract: Hyper-IgE syndrome (HIES) patients may share many features observed in severe atopic dermatitis (SAD), making a diagnostic dilemma for physicians. Determining clinical and laboratory markers that distinguish both disorders could provide early diagnosis and treatment.… read more here.
Keywords: laboratory markers; hyper ige; severe atopic; ige syndrome ... See more keywords
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2019.1682503
Abstract: Abstract Background Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective To assess dupilumab effectiveness and safety… read more here.
Keywords: safety; severe atopic; atopic dermatitis; dupilumab ... See more keywords
Tralokinumab for moderate-to-severe atopic dermatitis patients: first daily practice results.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and experimental dermatology"
DOI: 10.1093/ced/llad038
Abstract: BACKGROUND Evidence on tralokinumab treatment for moderate-to-severe atopic dermatitis (AD) in daily practice is limited. OBJECTIVES To report first experience with tralokinumab treatment in daily practice in AD patients. METHODS In this observational prospective study,… read more here.
Keywords: severe atopic; daily practice; moderate severe; tralokinumab treatment ... See more keywords
The role of access to care in acral lentiginous melanoma survival
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Dermatology"
DOI: 10.1111/bjd.15713
Abstract: osli S, Kostylina G et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008; 121:122–8. 7 Mendes AM, Costa ACC, Luz S et al. Omalizumab – one year experience in the treatment… read more here.
Keywords: atopic dermatitis; severe atopic; allergy; atopic ... See more keywords
Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Experimental Dermatology"
DOI: 10.1111/ced.14081
Abstract: Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signalling by binding specifically to the IL-4Rα subunit, shared by both the IL4 and IL-13 receptor complexes (1) recently introduced for the treatment… read more here.
Keywords: severe atopic; treatment; cold urticaria; atopic dermatitis ... See more keywords
Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.14066
Abstract: Cyclosporine A (CSA) is an immunosuppressant agent widely used in severe atopic dermatitis (AD). However, experience in children is limited. read more here.
Keywords: severe atopic; cyclosporine severe; atopic dermatitis; dermatitis children ... See more keywords
Association of Severe Atopic Dermatitis with month of birth in Armenian pediatric patients
Sign Up to like & getrecommendations! Published in 2018 at "Pediatric Allergy and Immunology"
DOI: 10.1111/pai.12918
Abstract: Atopic dermatitis (AD) is a chronic relapsing skin disease which affects 15-20% of children worldwide.(1) It is also considered as a major risk factor for developing other atopic diseases including food allergy, asthma and allergic rhinitis later in… read more here.
Keywords: dermatitis month; birth; month birth; atopic dermatitis ... See more keywords
Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Pharmacotherapy"
DOI: 10.1177/10600280221096713
Abstract: Objective The objective of this article is to review abrocitinib, an oral Janus kinase (JAK) 1 inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis (AD). Data Sources A literature search of MEDLINE (PubMed)… read more here.
Keywords: atopic dermatitis; severe atopic; fda approved; moderate severe ... See more keywords
Rates of cardiovascular events among patients with moderate-to-severe atopic dermatitis in an integrated health care system: A retrospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "PLOS ONE"
DOI: 10.1371/journal.pone.0277469
Abstract: Patients with versus without atopic dermatitis may have a greater risk of cardiovascular events, and the risk increases with severity of atopic dermatitis. The incidence of cardiovascular events in the population of patients with moderate-to-severe… read more here.
Keywords: severe atopic; moderate severe; atopic dermatitis; dermatitis ... See more keywords
Pilot Study of a Customized Nanotextile Wet Garment Treatment on Moderate and Severe Atopic Dermatitis: A Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2020 at "Pediatrics"
DOI: 10.1542/peds.2020-023861gg
Abstract: H He, MJ Koh, HY Lee, SB Ang. Pediatr Dermatol . 2020;37(1):52–57 To compare the use of nanotextile (100% nanopolyester) and viscose rayon (Tubifast) garments for wet wrap therapy (WWT) thereby demonstrating nanotextile as a… read more here.
Keywords: severe atopic; study; atopic dermatitis; moderate severe ... See more keywords